AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6719513
Drug: Conventional localization
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional localization for treatment volume
Trial: 27296126
Drug: Combined preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined preventive measures (CPM) including antibiotic prophylaxis with IV amoxicillin/clavulanate (1.2 g)
Trial: 15156418
Drug: Intravenous anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anaesthesia (TIVA)
Trial: 9840720
Drug: Corticosteroid co-medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid co-medication
Trial: 9840720
Drug: Docetaxel without
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel without corticosteroid co-medication
Trial: 9840720
Drug: Cumulative dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative dose of docetaxel
Trial: 8030804
Drug: nedocromil sodium,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nedocromil sodium, 2% ophthalmic solution, bid
Trial: 30903806
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment of severe wasting
Trial: 25447557
Drug: Intranasal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketamine at 1 mg/kg
Trial: 25447557
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl at 1.5 μg/kg
Trial: 15384808
Drug: ACEI (oral)
RxNorm normalized name: Veneno de Abeja Aceite de Vibora
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI (oral)
Trial: 15384808
Drug: ARB (oral)
RxNorm normalized name: revakinagene taroretcel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB (oral)
Trial: 15384808
Drug: Ca channel
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca channel blocker
Trial: 10626618
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (child only)
Trial: 10626618
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (mother only)
Trial: 10626618
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (mother and child)
Trial: 8748193
Drug: Continuous passive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous passive motion (CPM) for three 3‐h periods daily
Trial: 2202511
Drug: Ceftizoxime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftizoxime (1 gm single dose)
Trial: 2202511
Drug: Cefoxitin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (3 doses of 2 gm)
Trial: 19528280
Drug: PA-824 (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA-824 (1,500 mg single dose)
Trial: 19528280
Drug: PA-824 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA-824 (600 mg multiple doses)
Trial: 19528280
Drug: PA-824 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA-824 (up to 7 days of daily dosing)
Trial: 19528280
Drug: PA-824 (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA-824 (daily dosing)
Trial: 15068394
Drug: OGTT (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OGTT (oral glucose tolerance test; 75 g of glucose)
Trial: 3557017
Drug: Sulfated G‐17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfated G‐17 infusion
Trial: 3557017
Drug: Unsulfated G‐17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsulfated G‐17 infusion
Trial: 30506924
Drug: Mirtazapine transdermal
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine transdermal ointment 2 mg/cat, applied once daily for 14 ± 3 days
Trial: 30506924
Drug: Placebo, applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, applied once daily for 14 ± 3 days
Trial: 17329128
Drug: Dopamine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine administration
Trial: 10890672
Drug: Ibuprofen (cyclooxygenase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (cyclooxygenase inhibitor)
Trial: 7899118
Drug: Methylprednisolone (MP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP) 2 mg/kg IV
Trial: 3108981
Drug: Coughing during
RxNorm normalized name: Pediaclear Cough
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coughing during inhalation of nebulised distilled water
Trial: 21468376
Drug: Intravenous cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cefuroxime 1500 mg given as preoperative antimicrobial prophylaxis 30 minutes prior to surgery
Trial: 16705719
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg alendronate for 2 months and 10 mg for 2 months thereafter
Trial: 16705719
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg alendronate for 2 months and 10 mg for 4 months thereafter
Trial: 14740310
Drug: Propofol-LCT with
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol-LCT with pre-treatment of lidocaine
Trial: 14740310
Drug: Propofol-MCT/LCT with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-MCT/LCT with pre-treatment of lidocaine
Trial: 11501728
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (ice massage or wax packs, thermal baths, and faradic hand baths)
Trial: 11501728
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no physical or exercise therapy)
Trial: 9243041
Drug: Stopping antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stopping antibiotic therapy on day 3 (group A)
Trial: 9243041
Drug: Continuing antibiotic
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing antibiotic therapy (group B)
Trial: 3570863
Drug: Riboflavin supplement
RxNorm normalized name: Riboflavin supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riboflavin supplement
Trial: 3570863
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid supplement
Trial: 28545578
Drug: Mindfulness-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based intervention (MBI) involving eight workshops lasting 1.5 hours each, conducted weekly for 8 weeks.
Trial: 26136584
Drug: WEP group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WEP group with high water intake (>1200 mL/d)
Trial: 23670566
Drug: Counseling for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counseling for depression treatment
Trial: 21172952
Drug: BI 44370
RxNorm normalized name: BI 44370 TA
DrugBank: BI 44370 TA (DB16037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 44370 TA 400 mg
Trial: 21172952
Drug: BI 44370
RxNorm normalized name: BI 44370 TA
DrugBank: BI 44370 TA (DB16037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 44370 TA 200 mg
Trial: 21172952
Drug: BI 44370
RxNorm normalized name: BI 44370 TA
DrugBank: BI 44370 TA (DB16037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 44370 TA 50 mg
Trial: 16247610
Drug: Clotrimazole 100
RxNorm normalized name: clotrimazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole 100 mg vaginal pessaries for 6 days, 2 gm secnidazole, and 150 mg fluconazole as single therapy.
Trial: 16247610
Drug: Clotrimazole 100
RxNorm normalized name: clotrimazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole 100 mg vaginal pessaries for 6 days, combination kit containing 150 mg fluconazole, 2 gm secnidazole, and 1 gm azithromycin.
Trial: 12235022
Drug: Monosodium glutamate
RxNorm normalized name: Monosodium Glutamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monosodium glutamate (MSG) 150 mg/kg body weight
Trial: 10217372
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one tablet/day)
Trial: 8610776
Drug: Endocervical prostaglandin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocervical prostaglandin E2 gel
Trial: 540079
Drug: Tinidazole 40-50
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tinidazole 40-50 mg/kg for 3 days
Trial: 540079
Drug: Tinidazole 100
RxNorm normalized name: tinidazole 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole 100 mg coated tablets
Trial: 540079
Drug: Tinidazole 40-50
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tinidazole 40-50 mg/kg
Trial: 540079
Drug: Tinidazole for
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tinidazole for G. lamblia infections
Trial: 22670574
Drug: Cognitive-behavioral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral group therapy program
Trial: 17590368
Drug: Mud-bath treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mud-bath treatment (12 mud packs and 12 thermal baths over a period of two weeks)
Trial: 2112337
Drug: ISDN spray,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISDN spray, 2.5 mg
Trial: 2112337
Drug: sublingual NTG,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual NTG, 0.8 mg
Trial: 91774
Drug: Vaccinated group
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinated group (polyvalent pseudomonas vaccine)
Trial: 31401603
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal oxygen therapy (HFOT) alone
Trial: 31401603
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal oxygen therapy (HFOT) with non-invasive ventilation (NIV)
Trial: 29669181
Drug: Arm B
RxNorm normalized name: arm brace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B (70 Gy of radiation with cisplatin plus erlotinib at 150 mg daily)
Trial: 24598885
Drug: Vitamin B-12
RxNorm normalized name: Vitamin B-12
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B-12 supplementation (50 μg daily)
Trial: 22856186
Drug: Gel-bead delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel-bead delivery of Eimeria oocysts
Trial: 22856186
Drug: Oral gavage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral gavage of Eimeria oocysts
Trial: 22856186
Drug: Spray vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray vaccination with Eimeria oocysts mixture
Trial: 20738316
Drug: Intravenous ghrelin
RxNorm normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ghrelin (5 pmol/kg/min)
Trial: 18422391
Drug: High-dose valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose valsartan 160-320 mg/day
Trial: 18422391
Drug: Low-dose valsartan
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose valsartan 80 mg/day (VALVACE trial)
Trial: 10648316
Drug: 12-mL bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-mL bolus dose with a 25-min lockout interval
Trial: 10648316
Drug: 4-mL bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-mL bolus dose with an 8-min lockout interval
Trial: 9017785
Drug: 5-lipoxygenase inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-lipoxygenase inhibitors
Trial: 9017785
Drug: cysLT receptor
RxNorm normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cysLT receptor antagonists
Trial: 9017785
Drug: 5-lipoxygenase inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-lipoxygenase inhibitors and cysLT receptor antagonists
Trial: 8382228
Drug: pyrophosphate containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pyrophosphate containing cleaning gel
Trial: 3017551
Drug: Carmustine (BCNU)
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carmustine (BCNU) - 80 mg/m2 iv daily X 3 every 6 weeks
Trial: 3017551
Drug: Dacarbazine (DTIC)
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine (DTIC) - 175 mg/m2 iv daily X 5 every 4 weeks
Trial: 3017551
Drug: Procarbazine (PCB)
DrugBank: Procarbazine (DB01168)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Procarbazine (PCB) - 100 mg/m2 orally
Trial: 22549390
Drug: Jiedu granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiedu granules plus cinobufacini injection (CM group)
Trial: 20353469
Drug: 200 days
RxNorm normalized name: clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 days valganciclovir prophylaxis (900 mg once daily)
Trial: 20353469
Drug: 100 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 days valganciclovir prophylaxis (900 mg once daily)
Trial: 18419349
Drug: High-potency live-attenuated
RxNorm normalized name: varicella, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine
Trial: 15863796
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg i.m. of olanzapine
Trial: 15863796
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg i.m. of haloperidol
Trial: 11862501
Drug: Supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive care plus MLT (20 mg/day orally during the dark period)
Trial: 11862501
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus MLT (20 mg/day orally during the dark period)
Trial: 1918275
Drug: Intravenous urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous urokinase (UK) 72,000 IU injected over 10 minutes and UK 528,000 IU by drip infusion over 12 or 24 hours (UK group, n = 76)
Trial: 1918275
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy without urokinase (control group, n = 90)
Trial: 1918275
Drug: Intravenous urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous urokinase (UK) (UK group, n = 43)
Trial: 1918275
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy without urokinase (control group, n = 32)
Trial: 1918275
Drug: Intravenous urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous urokinase (UK) (UK group, n = 66)
Trial: 1918275
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy without urokinase (control group, n = 68)
Trial: 1918275
Drug: Intravenous urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous urokinase (UK) (UK group, n = 10)
Trial: 1918275
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy without urokinase (control group, n = 22)
Trial: 6130665
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of ordinary therapy until planned cholecystectomy under neurolept anaesthesia (n = 13)
Trial: 6130665
Drug: 4-day gradual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-day gradual withdrawal of beta-receptor blockers (n = 13)
Trial: 31163519
Drug: Methylprednisolone combined
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone combined with peripheral vestibular rehabilitation therapy
Trial: 9649009
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy (various regimens including intravenous mitomycin plus 5‐fluorouracil, oral 5‐FU, intravenous methotrexate plus 5‐FU, intravenous cisplatin plus 5‐FU, hepatic arterial infusion of 5‐FU plus oral 5‐FU)
Trial: 9649009
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no postoperative chemotherapy)
Trial: 7517720
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) as a single agent before conventional remission induction therapy
Trial: 23517517
Drug: Daily handwashing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily handwashing with soap, daily brushing with fluoride toothpaste, biannual deworming with 400 mg albendazole (Essential Health Care Program [EHCP])
Trial: 23517517
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (external concurrent control)
Trial: 16783467
Drug: Infusion rate
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion rate of IGIV-C, 10% at 0.14 mL/kg/min
Trial: 16783467
Drug: Infusion rate
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion rate of IGIV-C, 10% at 0.08 mL/kg/min (standard rate)
Trial: 16783467
Drug: Both rates
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both rates of infusion (0.08 mL/kg/min and 0.14 mL/kg/min)
Trial: 16783467
Drug: Increased rate
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased rate of infusion of IGIV-C, 10%
Trial: 16783467
Drug: Increased rate
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased rate of infusion of IGIV-C, 10% at 0.14 mL/kg/min
Trial: 7021412
Drug: Kallikrein treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kallikrein treatment
Trial: 30190369
Drug: Sorafenib +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib + modified FOLFOX (sorafenib 400 mg twice a day for 2 weeks, followed by mFOLFOX: 5-FU 1200 mg/m2/day for 46 hours, leucovorin 200 mg/m2, oxaliplatin 85 mg/m2 biweekly)
Trial: 25473939
Drug: AZD5423 (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5423 (75 or 300 μg) once daily for 7 days
Trial: 25473939
Drug: AZD5423 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5423 (300 μg)
Trial: 25473939
Drug: AZD5423 (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5423 (75 μg)
Trial: 25473939
Drug: Budesonide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (200 μg twice daily)
Trial: 24221838
Drug: In-hospital treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital treatments for AMI
Trial: 19772502
Drug: Indapamide retard
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide retard therapy for 8 weeks
Trial: 17519152
Drug: CARRA/LNG containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CARRA/LNG containing 0.75 mg LNG per 4 mL of gel
Trial: 17519152
Drug: CARRA/LNG containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CARRA/LNG containing 1.5 mg LNG per 4 mL of gel
Trial: 17519152
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of CARRA/LNG
Trial: 15219640
Drug: Propranolol pre-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol pre-treatment
Trial: 9642484
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blockers (CCBs) with pravastatin (lipid-lowering therapy)
Trial: 9642484
Drug: Pravastatin (lipid-lowering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (lipid-lowering therapy)
Trial: 2528022
Drug: Combined immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined immunosuppressive therapy (prednisone, cyclophosphamide, azathioprine)
Trial: 2528022
Drug: Membrane plasmapheresis
RxNorm normalized name: HAEMO-PAK UNIT FOR PLASMAPHERESIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Membrane plasmapheresis (in addition to immunosuppressive therapy)
Trial: 791477
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with disease confined to skin, subcutaneous tissue nodes, lung, or pleura